Jazz Pharmaceuticals Resultados de beneficios anteriores
Pasado controles de criterios 1/6
Jazz Pharmaceuticals ha aumentado sus beneficios a una tasa media anual de 6%, mientras que los beneficios de la industria de Pharmaceuticals han experimentado un crecimiento de 9.7% anual. Los ingresos han ido creciendo a una tasa media de 8.8% al año. La rentabilidad financiera de Jazz Pharmaceuticals es de 0.6%, y sus márgenes netos son de 0.7%.
Información clave
6.03%
Tasa de crecimiento de los beneficios
4.92%
Tasa de crecimiento del BPA
| Crecimiento de la industria Pharmaceuticals | 5.95% |
| Tasa de crecimiento de los ingresos | 8.82% |
| Rentabilidad financiera | 0.65% |
| Margen neto | 0.66% |
| Última actualización de beneficios | 31 Mar 2026 |
Actualizaciones de resultados anteriores recientes
Recent updates
Artículo de análisis • May 13
We Think You Can Look Beyond Jazz Pharmaceuticals' (NASDAQ:JAZZ) Lackluster Earnings
The market was pleased with the recent earnings report from Jazz Pharmaceuticals plc ( NASDAQ:JAZZ ), despite the...Artículo de análisis • May 08
Jazz Pharmaceuticals plc Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next
Jazz Pharmaceuticals plc ( NASDAQ:JAZZ ) investors will be delighted, with the company turning in some strong numbers...
Actualización de narrativa • Apr 28
JAZZ: HER2 GEA Data Will Support Future Oncology Leadership Thesis
Analysts have nudged the price target on Jazz Pharmaceuticals higher to about $226, reflecting updated views on margins, central nervous system revenue durability, and upcoming oncology contributions following recent Q4 results and refreshed models. Analyst Commentary Recent Street research on Jazz Pharmaceuticals has centered on refreshed models following Q4 results, updated revenue guidance, and the expected contribution from oncology assets alongside the core central nervous system portfolio.
Actualización de narrativa • Apr 13
JAZZ: CNS Cash Flows And Upcoming Oncology Launches Will Shape Execution Risks
Analysts have increased their average price target on Jazz Pharmaceuticals by $13 to $255, citing more supportive assumptions around revenue growth, profit margins and a slightly lower future P/E following the recent Q4 results and updated guidance. Analyst Commentary Recent research on Jazz Pharmaceuticals has largely centered on updated price targets and ratings following the company’s Q4 report and new guidance.Actualización de narrativa • Mar 30
JAZZ: CNS Cash Flows And HER2 Franchise Will Shape Oncology Execution Risks
Narrative Update on Jazz Pharmaceuticals Analysts have lifted price targets on Jazz Pharmaceuticals by roughly $10 to $45 into a $224 to $275 range, citing steady central nervous system demand, updated Ziihera and zanidatamab expectations following HERIZON-GEA data, and recent Q4 results that aligned with or modestly exceeded prior forecasts. Analyst Commentary Recent research on Jazz Pharmaceuticals has been broadly constructive, with several firms adjusting price targets higher after Q4 results and the HERIZON GEA data updates.Actualización de narrativa • Mar 16
JAZZ: HER2 Data And CNS Cash Flows Will Balance Oncology Execution Risks
The analyst price target for Jazz Pharmaceuticals has been adjusted slightly higher to reflect a $1 increase in fair value to $188, lower modeled revenue growth at 2.92%, a higher profit margin assumption at 21.90%, and a reduced future P/E of 13.95, as analysts point to a resilient central nervous system franchise, updated views on Ziihera and zanidatamab opportunities, and recent Q4 results and guidance. Analyst Commentary Recent research coverage points to generally constructive sentiment on Jazz Pharmaceuticals, with a cluster of higher price targets anchored to the company’s central nervous system portfolio and oncology pipeline, including Ziihera and zanidatamab.
Actualización de narrativa • Mar 02
JAZZ: Oncology Readouts And CNS Durability Will Drive Future Upside Potential
Our analyst fair value estimate for Jazz Pharmaceuticals has moved from $230.00 to about $263.59, as analysts factor in stronger margin expectations, a slightly higher discount rate, and ongoing Street enthusiasm around Ziihera and the broader oncology pipeline following recent Q4 updates and HERIZON-GEA data presentations. Analyst Commentary Recent Street research has leaned constructive on Jazz Pharmaceuticals, with multiple bullish analysts revisiting their models following Q4 results and the latest HERIZON-GEA data.Seeking Alpha • Feb 26
Jazz Pharmaceuticals: Relief Rally On 2026 Oxybate Franchise's Outlook
Summary Jazz Pharmaceuticals is positioned for long-term value creation, with a relief rally following Q4 2025 results and 2026 outlook for the oxybate business. Jazz expects Xywav revenues to be flat or up mid-single digits in 2026, despite generic Xyrem headwinds, with the oxybate franchise revenues projected at $1.8-1.9 billion. Strong Modeyso launch and robust Ziihera phase 3 data in first-line GEA set up new growth drivers, with Ziihera's U.S. launch anticipated in 2H 2026. Multiple expansion and valuation re-rating are possible as investors look past widespread availability of Xyrem generics, with Ziihera and other assets supporting (at least) mid-single-digit revenue growth. Read the full article on Seeking Alpha
Nueva narrativa • Feb 21
Beyond the Patent Cliff: Unlocking the Cash Machine
Jazz Pharmaceuticals (JAZZ), headquartered in Dublin, Ireland, enters 2026 as a highly efficient cash generator that the broader market seems to continually misunderstand. Following a massive 41% earnings beat late last year, the company is proving that it is successfully navigating the transition away from its legacy reliance on the sleep disorder drug Xyrem.Actualización de narrativa • Feb 16
JAZZ: HER2 Practice-Changing GEA Data Will Drive Future Oncology Leadership
Narrative Update Overview The analyst price target for Jazz Pharmaceuticals has moved higher, with our fair value estimate rising from $213 to $219.40 as analysts factor in stronger Ziihera and zanidatamab potential, supported by recent HERIZON-GEA data and updated Street research. Analyst Commentary Recent Street research on Jazz Pharmaceuticals has been largely constructive, with multiple firms updating their work after the detailed HERIZON-GEA-01 readout and related discussions around Ziihera and zanidatamab.Actualización de narrativa • Feb 02
JAZZ: Practice-Changing HER2 Data Will Drive Oncology Upside And Rebalance Legacy Risks
Analysts have raised their price targets on Jazz Pharmaceuticals by approximately $10 to $30 per share, citing what they describe as practice-changing HERIZON GEA data for Ziihera and a clearer oncology pipeline driver as key supports for the higher valuations. Analyst Commentary Across recent research notes, analysts have been revising their views on Jazz Pharmaceuticals primarily around the HERIZON GEA data for Ziihera and what it could mean for the oncology portfolio.Actualización de narrativa • Jan 19
JAZZ: Practice-Changing HER2 Data Will Rebalance Oncology Potential And Legacy Risks
Jazz Pharmaceuticals' updated analyst price target has edged down by US$1 to US$187 as analysts factor in slightly higher growth and margin assumptions, supported by recent HERIZON-GEA-01 data that they describe as practice changing for Ziihera and potentially supportive of new standard-of-care use across several HER2+ cancer settings. Analyst Commentary Across recent research, most firms are reacting to the HERIZON-GEA-01 data by lifting their Jazz Pharmaceuticals price targets and highlighting Ziihera and zanidatamab as key value drivers.Actualización de narrativa • Jan 05
JAZZ: Oncology Data Will Reshape Revenue Mix While Legacy Headwinds Persist
We are raising our Jazz Pharmaceuticals fair value estimate to $188 from $147 as analysts boost price targets following positive HERIZON-GEA-01 data for Ziihera, which they see as a potential new standard of care and a multibillion dollar revenue driver. Analyst Commentary Street research following the HERIZON-GEA-01 topline readout has turned broadly constructive on Jazz Pharmaceuticals, with multiple firms lifting price targets and reiterating positive ratings.Actualización de narrativa • Dec 18
JAZZ: HER2-Positive GEA Breakthrough Will Drive Future Oncology Leadership
Analysts have nudged their fair value estimate for Jazz Pharmaceuticals higher to $213.00 from $208.50, reflecting stronger long term revenue growth expectations and a richer future P/E multiple, supported by increasingly bullish views on Ziihera's potential to become a new standard of care in HER2 positive GEA and a key oncology growth driver. Analyst Commentary Bullish analysts are largely focused on the upside from Ziihera's HERIZON-GEA-01 data, with multiple research shops lifting price targets and embedding higher long term oncology growth into their models.Actualización de narrativa • Dec 04
JAZZ: HER2-Positive GEA Success Will Drive Future Oncology Leadership And Upside
Our fair value estimate for Jazz Pharmaceuticals has nudged higher to $208.50 from $206.38, reflecting analysts' upward revisions to price targets as they factor in expectations of stronger long term revenue growth and profitability. This is driven by Ziihera's potential as a new standard of care in HER2 positive GEA and broader oncology indications.Actualización de narrativa • Nov 20
JAZZ: Recent Positive Trial Data Will Drive Future Leadership In HER2-Positive Oncology
Analysts have increased their price target for Jazz Pharmaceuticals from approximately $186 to $206 per share. They cite improved revenue growth projections and recent strong clinical data supporting the potential of Ziihera as a standard-of-care therapy in HER2-positive cancers.Artículo de análisis • Nov 18
Improved Revenues Required Before Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Stock's 25% Jump Looks Justified
Despite an already strong run, Jazz Pharmaceuticals plc ( NASDAQ:JAZZ ) shares have been powering on, with a gain of...Actualización de narrativa • Aug 30
Emerging Therapies And Portfolio Expansion Will Shape Future Markets
Analysts have modestly raised their price targets for Jazz Pharmaceuticals, driven by growing confidence in Modeyso's commercial prospects and expanded market potential, partially offset by persistent challenges in other segments, resulting in a new consensus target of $186.47. Analyst Commentary Bullish analysts are increasingly positive on the commercial potential of Modeyso following its recent approval, citing higher-than-expected pricing, a dedicated launch strategy, and strong patient/prescriber interest.Artículo de análisis • Aug 09
Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Second-Quarter Results Just Came Out: Here's What Analysts Are Forecasting For This Year
Last week, you might have seen that Jazz Pharmaceuticals plc ( NASDAQ:JAZZ ) released its second-quarter result to the...Artículo de análisis • Jul 21
Lacklustre Performance Is Driving Jazz Pharmaceuticals plc's (NASDAQ:JAZZ) Low P/E
With a price-to-earnings (or "P/E") ratio of 14.2x Jazz Pharmaceuticals plc ( NASDAQ:JAZZ ) may be sending bullish...Artículo de análisis • Jul 03
Here's Why Jazz Pharmaceuticals (NASDAQ:JAZZ) Can Manage Its Debt Responsibly
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...Seeking Alpha • Dec 23
Jazz Pharmaceuticals: Should Sing A Better Tune In 2025
Summary Jazz Pharmaceuticals' stock moved nicely higher post-3Q24 report and FDA approval of zanidatamab, despite challenges in its narcolepsy franchise from Avadel's Lumryz. Jazz's neuroscience franchise faces declining Xyrem sales but sees growth in Xywav and Epidiolex. Oncology growth is driven by zanidatamab's approval and other key drugs like Rylaze and Zepzelca, crucial for achieving Vision 2025 sales goals. An updated analysis around Jazz Pharmaceuticals follows in the paragraphs below. Read the full article on Seeking AlphaSeeking Alpha • Nov 18
Jazz Pharmaceuticals: High Uncertainty, Low Risk
Summary Jazz Pharmaceuticals is transitioning from Xyrem to Xywav, a low-sodium version with lower cardiac risks but faces competition with more convenient dosing. Strong management with CEO Bruce Cozadd owning $50M+ in shares and a solid balance sheet with Net Debt/EBITDA under 3x. The stock was purchased at under 50% of Base Case NPV, making the downside risk in a Worst Case scenario very modest. Despite some uncertainty, strong financial results and promising pipeline data make the stock deeply undervalued and a continued hold. Read the full article on Seeking AlphaDesglose de ingresos y gastos
Desglose de ingresos y gastos
Cómo gana y gasta dinero Jazz Pharmaceuticals. Basado en los últimos beneficios reportados, en base a los últimos doce meses (LTM).
Historial de beneficios e ingresos
| Fecha | Ingresos | Beneficios | Gastos G+A | Gastos de I+D |
|---|---|---|---|---|
| 31 Mar 26 | 4,439 | 29 | 1,337 | 757 |
| 31 Dec 25 | 4,268 | -356 | 1,498 | 741 |
| 30 Sep 25 | 4,158 | -368 | 1,651 | 776 |
| 30 Jun 25 | 4,087 | -405 | 1,598 | 778 |
| 31 Mar 25 | 4,065 | 482 | 1,578 | 809 |
| 31 Dec 24 | 4,069 | 560 | 1,416 | 851 |
| 30 Sep 24 | 3,993 | 463 | 1,376 | 834 |
| 30 Jun 24 | 3,910 | 395 | 1,359 | 869 |
| 31 Mar 24 | 3,843 | 331 | 1,361 | 857 |
| 31 Dec 23 | 3,834 | 415 | 1,307 | 818 |
| 30 Sep 23 | 3,794 | 80 | 1,269 | 782 |
| 30 Jun 23 | 3,763 | -87 | 1,378 | 685 |
| 31 Mar 23 | 3,738 | -156 | 1,397 | 615 |
| 31 Dec 22 | 3,659 | -224 | 1,399 | 555 |
| 30 Sep 22 | 3,584 | -19 | 1,276 | 532 |
| 30 Jun 22 | 3,481 | -52 | 1,222 | 536 |
| 31 Mar 22 | 3,300 | -450 | 1,291 | 530 |
| 31 Dec 21 | 3,094 | -330 | 1,399 | 476 |
| 30 Sep 21 | 2,863 | -161 | 1,326 | 416 |
| 30 Jun 21 | 2,626 | 40 | 1,170 | 354 |
| 31 Mar 21 | 2,436 | 518 | 926 | 306 |
| 31 Dec 20 | 2,364 | 239 | 880 | 310 |
| 30 Sep 20 | 2,280 | 179 | 846 | 316 |
| 30 Jun 20 | 2,217 | 133 | 818 | 317 |
| 31 Mar 20 | 2,188 | 280 | 808 | 295 |
| 31 Dec 19 | 2,162 | 523 | 762 | 275 |
| 30 Sep 19 | 2,056 | 609 | 626 | 259 |
| 30 Jun 19 | 1,988 | 656 | 662 | 230 |
| 31 Mar 19 | 1,954 | 486 | 586 | 224 |
| 31 Dec 18 | 1,891 | 447 | 625 | 227 |
| 30 Sep 18 | 1,851 | 520 | 667 | 234 |
| 30 Jun 18 | 1,793 | 434 | 578 | 230 |
| 31 Mar 18 | 1,687 | 447 | 610 | 214 |
| 31 Dec 17 | 1,619 | 488 | 544 | 198 |
| 30 Sep 17 | 1,579 | 372 | 518 | 175 |
| 30 Jun 17 | 1,541 | 399 | 505 | 175 |
| 31 Mar 17 | 1,528 | 408 | 496 | 174 |
| 31 Dec 16 | 1,488 | 397 | 480 | 160 |
| 30 Sep 16 | 1,432 | 363 | 470 | 148 |
| 30 Jun 16 | 1,399 | 361 | 462 | 151 |
| 31 Mar 16 | 1,352 | 335 | 447 | 139 |
| 31 Dec 15 | 1,325 | 330 | 433 | 133 |
| 30 Sep 15 | 1,312 | 328 | 422 | 130 |
| 30 Jun 15 | 1,278 | 266 | 411 | 102 |
Ingresos de calidad: JAZZ tiene una única gran pérdida de $1.5B que afecta a sus resultados financieros de los últimos 12 meses de 31st March, 2026.
Margen de beneficios creciente: Los actuales márgenes de beneficio(0.7%) de JAZZ son inferiores a los del año pasado (11.9%).
Análisis del flujo de caja libre vs. Beneficios
Análisis del crecimiento de los beneficios en el pasado
Tendencia de beneficios: Los beneficios de JAZZ han crecido un 6% al año en los últimos 5 años.
Acelerando crecimiento: JAZZ ha tenido un crecimiento negativo de los beneficios en el último año, por lo que no puede compararse con su media de 5 años.
Beneficios vs. Industria: JAZZ tuvo un crecimiento negativo de los beneficios (-93.9%) durante el año pasado, lo que dificulta la comparación con la media de la industria Pharmaceuticals (-5%).
Rentabilidad financiera
Alta ROE: La rentabilidad financiera de JAZZ (0.6%) se considera baja.
Rentabilidad económica
Rendimiento del capital invertido
Descubre empresas con buenos resultados en el pasado
Análisis de la empresa y estado de los datos financieros
| Datos | Última actualización (huso horario UTC) |
|---|---|
| Análisis de la empresa | 2026/05/22 08:26 |
| Precio de las acciones al final del día | 2026/05/22 00:00 |
| Beneficios | 2026/03/31 |
| Ingresos anuales | 2025/12/31 |
Fuentes de datos
Los datos utilizados en nuestro análisis de empresas proceden de S&P Global Market Intelligence LLC. Los siguientes datos se utilizan en nuestro modelo de análisis para generar este informe. Los datos están normalizados, lo que puede introducir un retraso desde que la fuente está disponible.
| Paquete | Datos | Marco temporal | Ejemplo Fuente EE.UU. * |
|---|---|---|---|
| Finanzas de la empresa | 10 años |
| |
| Estimaciones del consenso de analistas | +3 años |
|
|
| Precios de mercado | 30 años |
| |
| Propiedad | 10 años |
| |
| Gestión | 10 años |
| |
| Principales avances | 10 años |
|
* Ejemplo para valores de EE.UU., para no EE.UU. se utilizan formularios y fuentes normativas equivalentes.
A menos que se especifique lo contrario, todos los datos financieros se basan en un periodo anual, pero se actualizan trimestralmente. Esto se conoce como datos de los últimos doce meses (TTM) o de los últimos doce meses (LTM). Más información.
Modelo de análisis y copo de nieve
Los detalles del modelo de análisis utilizado para generar este informe están disponibles en nuestra página de Github, también tenemos guías sobre cómo utilizar nuestros informes y tutoriales en Youtube.
Conozca al equipo de talla mundial que diseñó y construyó el modelo de análisis Simply Wall St.
Métricas industriales y sectoriales
Simply Wall St calcula cada 6 horas nuestras métricas sectoriales y de sección. Los detalles de nuestro proceso están disponibles en Github.
Fuentes analistas
Jazz Pharmaceuticals plc está cubierta por 48 analistas. 18 de esos analistas presentaron las estimaciones de ingresos o ganancias utilizadas como datos para nuestro informe. Las estimaciones de los analistas se actualizan a lo largo del día.
| Analista | Institución |
|---|---|
| Brian Skorney | Baird |
| Joel Beatty | Baird |
| null null | Baird |